Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUIN MCL-321: pirtobrutinib versus investigator's choice covalent BTK inhibitor in previously treated BTK inhibitor-naive mantle cell lymphoma
CTR20212310Phase 3Active
- Sponsor
- Loxo Oncology
- Start
- Jan 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pirtobrutinib, ibrutinib, zanubrutinib in mantle cell lymphoma (MCL), sponsored by Loxo Oncology. Started Jan 2022; status: active.
02
Drugs
pirtobrutinibibrutinibzanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20212310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212310.